Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2026

Feb 18, 2026

30291_dirs_2026-02-17_448738c4-c122-49a3-bee0-e17fc7f6dd57.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2026-02-13

Reporting Person: Viehbacher Christopher (Director, President and CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-13 Restricted Stock Unit $0 A 38015 Acquired 2029-02-13 Common Stock (38015) Direct

Footnotes

F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.